Mysimba (Bupropion Hydrochloride, Naltrexone Hydrochloride)

Bupropion hydrochloride and naltrexone hydrochloride, the active ingredients in Mysimba, are a bupropion/naltrexone combination presented as tablets for oral use. They are indicated as an adjunct to diet and exercise for chronic weight management in adults with a body‑mass index of 30 kg/m² or higher, or 27 kg/m² with at least one weight‑related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia.

GNH USA supplies Mysimba as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics across the globe worldwide.

Mysimba acts on appetite regulation and energy balance pathways to support weight reduction in eligible adults. - Obesity (BMI ≥30 kg/m²): supports weight loss when combined with diet and exercise. - Overweight with comorbidity (BMI ≥27 kg/m²): aids weight reduction in patients with hypertension, type 2 diabetes, or dyslipidaemia. - Weight‑management adjunct: improves metabolic parameters such as blood glucose and lipid profiles when used with lifestyle changes.

Mysimba may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that often occurs early in treatment. - Headache: transient cranial pain that may resolve without intervention. - Constipation: reduced bowel movements leading to abdominal discomfort. - Dry mouth: decreased salivation causing a feeling of thirst. - Insomnia: difficulty falling or staying asleep, reported by some patients.

Serious or Rare Side Effects: - Seizures: potential convulsive episodes, particularly at higher doses or in predisposed individuals. - Suicidal thoughts: emergence of depressive ideation or behavior requiring immediate evaluation. - Severe allergic reaction: rash, swelling, or anaphylaxis that may need emergency care. - Elevated blood pressure: significant rise in systolic or diastolic pressure requiring monitoring.

When prescribing Mysimba, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate blood pressure and heart disease before initiating therapy. - Seizure risk: avoid use in patients with a history of seizures or eating disorders. - Psychiatric monitoring: watch for mood changes, depression, or suicidal ideation. - Drug interactions: review concomitant medications that lower seizure threshold or affect neurotransmitters. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Mysimba can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis when combined with bupropion. - Other opioid antagonists: may reduce the therapeutic effect of naltrexone. - Seizure‑lowering drugs: concurrent use can increase seizure risk.

Moderate Interactions (Monitor Closely): - CYP2B6 inhibitors (e.g., clopidogrel): may raise bupropion plasma levels. - CYP3A4 inducers (e.g., rifampin): may decrease naltrexone concentrations. - Antidepressants affecting serotonin: monitor for additive central nervous system effects.